Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?
This is a three-center, randomized, double-blind, fixed dose study designed to assess the efficacy, safety, and tolerability of a switch to vilazodone for sexual dysfunction associated with use of a selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI)compared to switching to sertraline in patients with Major Depressive Disorder (MDD).
Vilazodone is a newly introduced, FDA approved antidepressant that is a combined serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist. In contrast to the SSRIs and SNRIs, appears to have low adverse effects on sexual functioning when compared to placebo.
Major Depressive Disorder
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction|
- Changes in Sexual Functioning Questionnaire (CSFQ (c)) [ Time Frame: Baseline-11 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||June 2017|
|Estimated Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
Other Name: Viibryd
Active Comparator: Sertraline
Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
Other Name: Zoloft
The design will be a randomized, double blind study with patients being randomized to switching to either vilazodone or sertraline. This will consist of a 1-week Screening phase, a 2-week Cross Taper phase, an 8-week Treatment phase, and an optional 2-week Down taper phase. The total duration of each patient's participation will be 13 weeks.
Seventy-two patients will be randomized at the Baseline visit to either vilazodone or sertraline, 24 at each of the 3 sites. Patients will be recruited over 12 months.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01856127
|Contact: Rajnish Mago, MDemail@example.com|
|Contact: Kelly Huhn, BSfirstname.lastname@example.org|
|United States, Pennsylvania|
|Thomas Jefferson University||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Kelly Huhn, BS 215-503-1662 email@example.com|
|Contact: Tania Ruggiero 215-955-9474 firstname.lastname@example.org|
|Principal Investigator: Rajnish Mago, MD|
|University of Pennsylvania||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Lalita Luthra 215-746-6419 email@example.com <firstname.lastname@example.org>;|
|Principal Investigator: Michael Thase, MD|
|United States, Virginia|
|University of Virginia||Recruiting|
|Charlottesville, Virginia, United States, 22908|
|Contact: Dea Papajorgji 434-243-4646 DP3FC@hscmail.mcc.virginia.edu|
|Principal Investigator: Anita Clayton, MD|
|Principal Investigator:||Rajnish Mago, MD||Thomas Jefferson University|
|Principal Investigator:||Michael Thase, MD||University of Pennsylvania|
|Principal Investigator:||Anita Clayton, MD||University of Virginia|